Structure Therapeutics (NASDAQ:GPCR) Now Covered by Analysts at Wolfe Research

Wolfe Research began coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a research note issued to investors on Thursday, MarketBeat Ratings reports. The brokerage issued a peer perform rating on the stock.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Thursday, January 22nd. HC Wainwright cut their target price on shares of Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, March 16th. BMO Capital Markets set a $145.00 price target on Structure Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, March 17th. Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Finally, Guggenheim raised their price target on Structure Therapeutics from $90.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Structure Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $110.00.

Structure Therapeutics Stock Performance

NASDAQ GPCR opened at $46.20 on Thursday. Structure Therapeutics has a one year low of $13.22 and a one year high of $94.90. The firm has a market cap of $3.27 billion, a price-to-earnings ratio of -58.48 and a beta of -1.80. The firm has a 50 day simple moving average of $69.65 and a 200-day simple moving average of $51.21.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14). Equities analysts predict that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

A number of large investors have recently made changes to their positions in the stock. Osaic Holdings Inc. boosted its position in Structure Therapeutics by 101.9% during the second quarter. Osaic Holdings Inc. now owns 63,362 shares of the company’s stock worth $1,314,000 after acquiring an additional 31,972 shares during the last quarter. Aberdeen Group plc grew its position in Structure Therapeutics by 46.1% during the third quarter. Aberdeen Group plc now owns 586,869 shares of the company’s stock valued at $16,432,000 after acquiring an additional 185,245 shares during the period. Jefferies Financial Group Inc. acquired a new stake in Structure Therapeutics during the 3rd quarter worth approximately $4,770,000. Birchview Capital LP acquired a new stake in shares of Structure Therapeutics in the second quarter worth $747,000. Finally, Private Capital Advisors Inc. acquired a new stake in Structure Therapeutics in the 3rd quarter valued at $1,545,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.